Drug-virus interaction: Effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model

Cancer Gene Therapy

Volumn 16, Issue 5, 2009, Pages 405-414

  Wonganan, P ^a   Zamboni, W C ^b   Strychor, S ^c   Dekker, J D ^a   Croyle, M A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; Cancer; Cytochrome P450; Docetaxel; Liver; Pharmacokinetics

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; BETA GALACTOSIDASE; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; DOCETAXEL; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; EMBRYO; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VECTORS; LIVER; MALE; MEMBRANE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS; TRANSAMINASES;

ADENOVIRIDAE; ANIMALIA; RATTUS;

EID: 65049085743     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.99     Document Type: Article

References (53)

1. Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 2002; 16: 3-10.
2. Cao H, Koehler DR, Hu J. Adenoviral vectors for gene replacement therapy. Viral Immunol 2004; 17: 327-333.
3. Vattemi E, Claudio PP. Adenoviral gene therapy in head and neck cancer. Drug News Perspect 2006; 19: 329-337.
4. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027.
5. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Adenovirusmediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 1999; 44: 143-151.
6. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with nonsmall-cell lung cancer. J Clin Oncol 2000; 18: 609-622.
7. Inoue A, Narumi K, Matsubara N, Sugawara S, Saijo Y, Satoh K et al. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett 2000; 157: 105-112.
8. Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin HS et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 2004; 114: 1871-1879.
9. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Aran B, Booser DJ et al. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 2006; 107: 935-944.
10. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114.
11. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56: 1296-1302.
12. Fujita K Cytochrome P450 and anticancer drugs. Curr Drug Metab 2006; 7: 23-37.
13. Callahan SM, Ming X, Lu SK, Brunner LJ, Croyle MA. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J Pharmacol Exp Ther 2005; 312: 492-501.
14. Callahan SM, Boquet MP, Ming X, Brunner LJ, Croyle MA. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. J Gene Med 2006; 8: 566-576.
15. Fujitaka K, Oguri T, Isobe T, Fujiwara Y, Kohno N. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol 2001; 48: 4246.
16. Nallani SC, Goodwin B, Buckley AR, Buckley DJ, Desai PB. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 2004; 54: 219-229.
17. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485-495.
18. Gabrilovich DI. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 2006; 6: 823-832.
19. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006; 6: 546-558.
20. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin. Oncol 2002; 20: 3683-3690.
21. Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2007; 18: 168-172.
22. Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001; 48: 115-122.
23. Wang Y, Hu JK, Krol A, Li YP, Li CY, Yuan F. Systemic dissemination of viral vectors during intratumoral injection. Mol Cancer Ther 2003; 2: 1233-1242.
24. Wang Y, Yang Z, Liu S, Kon T, Krol A, Li CY et al. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer 2005; 92: 1414-1420.
25. Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 2008; 9: 129-143.
26. Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 2002; 87: 681-686.
27. DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH. Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecol Oncol 2008; 108: 355-360.
28. Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, Eiseman JL. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemother Pharmacol 2008; 62: 417-426.
29. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P et al. Substitution ofhexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 2008; 16: 1474-1480.
30. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397409.
31. Li Y, Okegawa T, Lombardi DP, Frenkel EP, Hsieh JT. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. J Urol 2002; 167: 339-346.
32. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-148.
33. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007; 24: 918-933.
34. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet 2006; 45: 235-252.
35. Won KA, Baumann H. The cytokine response element of the rat alpha 1-acid glycoprotein gene is a complex of several interacting regulatory sequences. Mol Cell Biol 1990; 10: 3965-3978.
36. Smith JS, Tian J, Lozier JN, Byrnes AP. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther 2004; 9: 932-941.
37. Le HT, Boquet MP, Clark EA, Callahan SM, Croyle MA. Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose. Hum Gene Ther 2006; 17: 1095-1111.
38. Imaoka S, Hashizume T, Funae Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab Pharmacokinet 2005; 20: 478-484.
39. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123-149.
40. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005; 1: 629-640.
41. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008; 245: 194-205.
42. Amacher DE. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 1998; 27: 119-130.
43. Callahan SM, Wonganan P, Croyle MA. Molecular and Macromolecular Alterations of Recombinant Adenoviral Vectors Do Not Resolve Changes in Hepatic Drug Metabolism During Infection. Virol J 2008; 5: 111.
44. Schaller M, Hogaboam CM, Lukacs N, Kunkel SL. Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response. J Allergy Clin Immunol 2006; 118: 295-302; quiz 303-294.
45. Seemungal TA, Wedzicha JA. Viral infections in obstructive airway diseases. Curr Opin Pulm Med 2003; 9: 111-116.
46. Shirali GS, Ni J, Chinnock RE, Johnston JK, Rosenthal GL, Bowles NE et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001; 344: 1498-1503.
47. Maizel Jr JV, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968; 36: 115-125.
48. Boquet MP, Wonganan P, Dekker JD, Croyle MA. Impact of Route of Systemic Administration of Adenovirus on Virus-Mediated Toxicity: Focus on Mortality, Virus Distribution, and Drug Metabolism, J Pharmacol Toxicol Methods 2008; 58: 222-232.
49. Coon MJ, van der Hoeven TA, Dahl SB, Haugen DA. Two forms of liver microsomal cytochrome P-450, P-4501m2 and P450LM4 (rabbit liver). Methods Enzymol 1978; 52: 109-117.
50. van der Hoeven T. Assay of Hepatic Microsomal Testosterone Hydroxylases by High-Performance Liquid Chromatography. Anal Biochem 1984; 138: 57-65.
51. Yang Y, Raper SE, Cohn JA, Engelhardt JF, Wilson JM. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA 1993; 90: 4601-4605.
52. Ahn WS, Bae SM, Lee JM, Namkoong SE, Yoo JY, Seo YS et al. Anti-cancer effect of adenovirus p53 on human cervical cancer cell growth in vitro and in vivo. Int J Gynecol Cancer 2004; 14: 322-332.
53. Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783:231-236.